AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01000792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
Study NCT01000792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Levocetirizine
Study NCT02314559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manual titration of propofol
Description: One group will be sedated with a manual titration technique: here the titration of propofol is done manually by the anesthetist. Dosages may range between 50 and 400mg, given by boluses of 20-50mg.
Study NCT02314559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Target controlled infusion of propofol
Description: The other group will be sedated with a target controlled infusion technique (pump, marsh or Schneider). The anesthetist can titrate indirectly by adjusting the target controlled infusion to achieve adequate sedation. The concentrations of propofol may vary between 2 and 6 µg/ml, achieved by increments of 0.5-1.5 µg/ml.
Study NCT00976924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood glucose monitor
Description: Blood glucose monitor is used to monitor the blood glucose level of the human-being.
Study NCT00976924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blood glucose monitor
Description: Blood glucose monitor is used to monitor the blood glucose level of the human-being.
Study NCT04242524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Clock Alignment
Description: Use timed lights and meals to align the circadian clock
Study NCT04242524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Circadian Clock Control
Description: No circadian clock alignment
Study NCT02424877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SandRA
Description: SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.
Study NCT02754440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel System with Version 7.0 Software
Description: Platelet Apheresis Procedure
Study NCT03317015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone XRG5029
Description: Pharmaceutical form: spray solution~Route of administration: nasal
Study NCT03317015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone
Description: Pharmaceutical form: spray solution~Route of administration: nasal
Study NCT00560170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin (Zocor)
Description: 40mg of Simvastatin (n=20) orally per-day for 28 days
Study NCT00560170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg/10mg of Ezetimibe/Simvastatin (Vytorin)
Description: 10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
Study NCT00500513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scans
Description: CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.
Study NCT00500513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implanted markers
Description: Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope
Study NCT00500513 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Treatment (RT)
Description: Radiotherapy incorporating respiratory treatment delivery
Study NCT03677557 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 16,5% Cutaquig
Description: Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig
Study NCT02328638 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parent Education Program
Description: The PEP intervention consists of didactic sessions regarding basic information about Autism Spectrum Disorders.
Study NCT02328638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual-based Behavioral Treatment
Description: The Manual-based Interdisciplinary Behavioral Treatment consists of nutritional and behavioral interventions to improve dietary intake (increase water, decrease sweetened beverages and snack foods, improve balanced diet), increase exercise, and teach behavioral strategies to address barriers to these goals.
Study NCT02647996 — intervention group
Intervention type: PROCEDURE
Intervention: MRI: functional (resting state) and structural (DTI)
Description: One hour brain MRI recording without active task for the patient, no sedation
Study NCT02577718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin-citrate-ethanol (NiCE)
Description: Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
Study NCT02849899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening).~In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning).~Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week.~The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin.
Study NCT02849899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.
Study NCT00275509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Study NCT00275509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Study NCT00275509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
Study NCT00275509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 2 gm/day. Standard of care
Study NCT00275509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: To achieve serum level of 8-10 ng/ml.
Study NCT00275509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses
Study NCT00275509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Taper over three months to 5 mg daily
Study NCT00275509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytogam
Description: Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
Study NCT01967576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: 5 mg twice a day on a 28-day cycle.
Study NCT02874989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib + Quercetin
Study NCT02874989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01814267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: Intervention group: care and follow-up through telemedicine (e-consultations)~* 1 hospital consultation at inclusion time, week 0~* then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.~* 1 hospital consultation to validate that the wound is well-healed
Study NCT01814267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: conventional group: iterative diabetes physicians consultations at hospital~* 1 consultation at inclusion time, week 0~* 1 consultation 2 weeks after inclusion, week 2~* 1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period~* 1 consultation to validate that the wound is well-healed
Study NCT01686399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and Activity Promotion
Description: Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
Study NCT02772367 — intervention group
Intervention type: PROCEDURE
Intervention: skin punch biopsy
Study NCT02858362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezutromid
Description: Administered orally.
Study NCT03441815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8
Study NCT03441815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02064101 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal Fusion
Description: The investigators are studying the use of triggered EMG via the IPC POWEREASE screwdriver (Product Codes HBE, HWE, GWF) during spinal fusion surgery in adolescent idiopathic scoliosis by comparing it to the traditional triggered EMG OrthoMon probe system (Product Codes GWF, IKN).
Study NCT02369796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection
Study NCT03281200 — intervention group
Intervention type: DRUG
Intervention: L - Antineoplastic and immunomodulating agents
Description: L - Antineoplastic and immunomodulating agents
Study NCT03281200 — intervention group
Intervention type: DRUG
Intervention: L01 - Antineoplastic agents
Description: L01 - Antineoplastic agents
Study NCT03281200 — intervention group
Intervention type: DRUG
Intervention: L01X - Other antineoplastic agents
Description: L01X - Other antineoplastic agents
Study NCT03281200 — intervention group
Intervention type: DRUG
Intervention: L01XE - Protein kinase inhibitors
Description: L01XE - Protein kinase inhibitors
Study NCT03281200 — intervention group
Intervention type: DRUG
Intervention: L01XE31 - Nintedanib
Description: L01XE31 - Nintedanib
Study NCT04601649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Talk
Description: The study is designed to provide education, support, and referrals for PrEP.
Study NCT03903588 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Imaging of the Retina
Study NCT01823016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, taken once daily
Study NCT01823016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168
Description: JNJ-38518168, 30 mg tablet, taken once daily
Study NCT03143062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NEWS
Description: NEWS
Study NCT02094924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK587323
Description: Single dose of FDC tablet formulation to be taken orally.
Study NCT02094924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
Description: Single dose of FDC tablet formulation to be taken orally
Study NCT03916913 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local radiation therapy
Description: Local radiotherapy on all sites of disease including primary and metastatic lesions
Study NCT03751917 — intervention group
Intervention type: DRUG
Intervention: Arsenic Trioxide
Description: This is an observational study. Patients who have received or are receiving all trans retinoic acid (ATRA) + Arsenic Trioxide will be followed and analyzed.
Study NCT05419778 — intervention group
Intervention type: DEVICE
Intervention: Osteogen plug®
Description: A type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)
Study NCT05419778 — intervention group
Intervention type: DEVICE
Intervention: MInerOss®
Description: A cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane.
Study NCT01421615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal capsules of lactobacilli
Description: The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.
Study NCT01421615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal capsules of lactobacilli
Description: The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.
Study NCT01421615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal capsules of lactobacilli
Description: The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
Study NCT01421615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal capsules of lactobacilli
Description: The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
Study NCT02912689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilator Assist
Description: NAVA during Non-invasive ventilation
Study NCT02912689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure support ventilation
Description: PS during Non-invasive ventilation
Study NCT02290249 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: Manikin was intubated by different novice personal with glidescope videolaryngoscope
Study NCT02290249 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: Pediatric manikin was intubated by novice personal with airtraq
Study NCT02170103 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: percutaneous intervention (PCI)
Description: Successful PCI with the patent vessel and at least Thrombolysis in Myocardial Infarction (TIMI) 2 flow in the left anterior descending artery (LAD) post-PCI.
Study NCT02170103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous intervention (PCI)
Description: Successful PCI with the patent vessel and at least Thrombolysis in Myocardial Infarction (TIMI) 2 flow in the left anterior descending artery (LAD) post-PCI.
Study NCT02170103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbubbles
Description: The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.
Study NCT02170103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Intermittent high Mechanical Index (MI) impulses (0.8-1.4 MI; Frequency 1.0-1.7 MegaHertz (MHz); pulse duration 4-44 microseconds) will be administered over the microvasculature where there are wall motion abnormalities and a perfusion defect using an imaging plane that best aligns itself with the risk area
Study NCT02062840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity whole-body infrared heating
Description: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
Study NCT02062840 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low intensity whole-body infrared heating
Description: Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
Study NCT02062840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)
Description: A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.
Study NCT02062840 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)
Description: A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.
Study NCT02062840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.
Study NCT02062840 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaires
Description: Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.
Study NCT02222948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatelizumab
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT02222948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Vatelizumab)
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT03619720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Records
Description: Respiratory records, Vocal records Video records Questionnaires
Study NCT02661334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace
Study NCT02661334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Flour
Description: rice flour powder matched for color, appearance, taste, and solubility
Study NCT02661334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice Flour
Description: rice flour powder matched for color, appearance, taste, and solubility
Study NCT03488017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ocular Coil
Description: Non-invasive ocular device
Study NCT02945488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise intervention will entail 30 minutes of moderate intensity cardiovascular training 3 days/week and full body resistance training 2 days/week (supervised). Cardiovascular training will entail any weight-bearing activity that would achieve target heart rate, such as walking, jogging, stair climbing, dancing, etc. Resistance training will entail 2-3 sets of 8-12 repetitions of exercises targeting all major muscle groups with an external load applied, such as a dumbbell, barbell, medicine ball, etc.
Study NCT02945488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary plan
Description: Mediterranean dietary plan, which contains foods, such as fish, vegetables, nuts, and oils, which are anti-inflammatory in nature.
Study NCT02945488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.
Study NCT02945488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.
Study NCT02403648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-961
Description: BIOD-961 is a lyophilized glucagon formulation.